MedTrace Logo

Whole Genome Sequencing in Breast Cancer

NCT06334471 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2024-04-03

No results posted yet for this study

Summary

This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030.

Conditions

Interventions

OTHER

no intervention needed

no intervention needed

Sponsors & Collaborators

  • Inocras Korea Inc.

    lead INDUSTRY

Principal Investigators

  • JeongSeok Lee · Inocras Korea Inc.

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2025-08-02
Completion
2030-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06334471 on ClinicalTrials.gov